Skip to main content

Scorpion venom to shuttle drugs into the brain

Images

Participants

Image
Research Associate
Tel.+34 93 40 34805
Image
Emeritus Professor
Tel.+34 93 40 37125
Image
Postdoctoral Fellow
Tel.+34 93 40 37127
Image
Monica Varese
Postdoctoral Fellow
Tel.+34 93 40 37127
Image
Postdoctoral Fellow
Tel.+34 93 40 37127
Image
Research Associate
Tel.+34 93 40 37127

Contact

Image
Press & Communications Section Head
Tel.+34 93 40 37255

Researchers at IRB Barcelona modify chlorotoxin—a small protein present in scorpion venom with blood-brain barrier permeability—to transport drugs into the brain. 

The barrier, which protects the brain, prevents drugs used for the treatment of neurological diseases and brain tumours from entering the organ.

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a small protein (a peptide)  derived from chlorotoxin, found in scorpion venom (Giant Yellow Israeli scorpion), to carry drugs across the blood-brain barrier (BBB).

The barrier serves to protect the brain from toxic substances, but it also prevents many potential drugs for the treatment of neurological diseases and tumours from entering this organ. “About 98% of drugs that could have therapeutic applications cannot be used because they cannot cross this barrier,” explains the head of the lab, Ernest Giralt.

The researchers have chemically synthesised chlorotoxin and a series of analogues that retain some of the properties ofas the parent peptide. They have studied the efficiency of these compounds in cell models of the BBB and have demonstrated that the peptide called MiniCTX3 has the capacity to transport compounds of different nature across the BBB “with great efficiency”.

Animal venoms for the brain

In the same way that traditional medicine uses natural products such as plants and flowers to treat a range of diseases, the IRB Barcelona lab has sought inspiration from venoms with the objective of identifying peptide shuttles. “Our goal is to enable drugs to enter the brain and to do this we bind them to peptides specifically designed to cross the BBB. The conjugation of these drugs to the shuttles would improve their efficacy,” says Meritxell Teixidó, co-leader of the research.  “There are only two or three groups worldwide devoted to shuttle peptides. We are working on a number of strategies and one of them is venoms,” says Giralt.

In previous studies, these scientists inspired in a peptide from bee venom, namely apamin, had made some chemical modifications and obtained a shuttle with BBB permeability.

After these positive results, the lab wanted to address whether venoms could provide a universal source of peptide shuttles. “Thousands of venoms that hold millions of peptides with the shuttle potential have been described. We chose chlorotoxin because it has already been reported that it acts like a toxin in the brain,” explains Teixidó.

This study is another example of ground-breaking research finding inspiration in nature and it has produced another shuttle that can enhance drug transport into the brain.

The research was funded by the Ministry of Science, through ERDFs, and the Catalan Government.

 

Reference article:

Cristina Díaz-Perlas,  Monica Varese,  Salvador Guardiola,  Jesús García,  Macarena Sánchez-Navarro,  Ernest Giralt and  Meritxell Teixidó

From venoms to BBB-shuttles. MiniCTX3: a molecular vector derived from scorpion venom

Chemical Communications (2018) DOI: 10.1039/C8CC06725B

 

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).